Abstract
Engraftment after hematopoietic stem cell transplant (HSCT) appears to occur as “overlapping waves” of hematopoiesis. Initial increases in absolute neutrophil counts result from a transferred population of relatively mature committed progenitor cells that are capable of only transient engraftment. Immature multipotent stem cells generate the second phase of neutrophil engraftment. Finally, pluripotent stem cells from the transplanted graft sustain trilineage hematopoiesis. Generally, engraftment begins to be observed 10–21 days after the stem cell infusion. Engraftment kinetics can be influenced by a number of factors including the underlying disease, pre-HSCT therapy, conditioning regimen, use of cytokines post HSCT, graft quality, and post-HSCT complications/events (e.g., graft-versus-host disease (GVHD), medications, infections).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Bibliography
FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing, and Administration. 2008.
Spitzer T. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:893–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Murray, S. (2015). Engraftment. In: Maziarz, R., Slater, S. (eds) Blood and Marrow Transplant Handbook. Springer, Cham. https://doi.org/10.1007/978-3-319-13832-9_14
Download citation
DOI: https://doi.org/10.1007/978-3-319-13832-9_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-13831-2
Online ISBN: 978-3-319-13832-9
eBook Packages: MedicineMedicine (R0)